JP2024528417A - フィラミンａ（ｆｌｎａ）をサイレンシングするためのｉｒｎａ組成物および方法 - Google Patents

フィラミンａ（ｆｌｎａ）をサイレンシングするためのｉｒｎａ組成物および方法 Download PDF

Info

Publication number
JP2024528417A
JP2024528417A JP2023577564A JP2023577564A JP2024528417A JP 2024528417 A JP2024528417 A JP 2024528417A JP 2023577564 A JP2023577564 A JP 2023577564A JP 2023577564 A JP2023577564 A JP 2023577564A JP 2024528417 A JP2024528417 A JP 2024528417A
Authority
JP
Japan
Prior art keywords
nucleotides
dsrna agent
nucleotide
strand
antisense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528417A5 (https=
Inventor
ブラウン，カーク
カストレノ，アダム
ディ マキニンチ，ジェイムズ
エム グエン，トゥエン
ケイ シュリーゲル，マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alnylam Pharmaceuticals Inc
Original Assignee
Alnylam Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alnylam Pharmaceuticals Inc filed Critical Alnylam Pharmaceuticals Inc
Publication of JP2024528417A publication Critical patent/JP2024528417A/ja
Publication of JP2024528417A5 publication Critical patent/JP2024528417A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023577564A 2021-06-23 2022-06-23 フィラミンａ（ｆｌｎａ）をサイレンシングするためのｉｒｎａ組成物および方法 Pending JP2024528417A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163214220P 2021-06-23 2021-06-23
US63/214,220 2021-06-23
US202163274248P 2021-11-01 2021-11-01
US63/274,248 2021-11-01
PCT/US2022/034765 WO2022271972A1 (en) 2021-06-23 2022-06-23 Irna compositions and methods for silencing filamin a (flna)

Publications (2)

Publication Number Publication Date
JP2024528417A true JP2024528417A (ja) 2024-07-30
JP2024528417A5 JP2024528417A5 (https=) 2025-07-01

Family

ID=84545942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577564A Pending JP2024528417A (ja) 2021-06-23 2022-06-23 フィラミンａ（ｆｌｎａ）をサイレンシングするためのｉｒｎａ組成物および方法

Country Status (4)

Country Link
US (1) US20240301418A1 (https=)
EP (1) EP4359522A4 (https=)
JP (1) JP2024528417A (https=)
WO (1) WO2022271972A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840703B2 (en) * 2013-01-11 2017-12-12 Children's Medical Center Corporation Methods and compositions for the production of siRNAs
EP3171858A4 (en) * 2014-07-24 2018-07-25 Memorial Sloan-Kettering Cancer Center Method and composition for targeted delivery of therapeutic agents
KR101734652B1 (ko) * 2015-06-10 2017-05-11 성균관대학교산학협력단 독소루비신 내성 관련 유전자 및 이의 용도
US20190262469A1 (en) * 2015-09-04 2019-08-29 C. Jeffrey Brinker Protocells to treat microbial infection and for synergistic delivery
MX2020011570A (es) * 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.
KR20220115995A (ko) * 2019-12-13 2022-08-19 알닐람 파마슈티칼스 인코포레이티드 인간 염색체 ９ 개방 판독 프레임 72 (C9orf72) iRNA 제제 조성물 및 이의 사용 방법
US20230045629A1 (en) * 2020-01-15 2023-02-09 National University Corporation Tokai National Higher Education And Research System Treatment of progressive supranuclear palsy

Also Published As

Publication number Publication date
WO2022271972A1 (en) 2022-12-29
EP4359522A1 (en) 2024-05-01
US20240301418A1 (en) 2024-09-12
EP4359522A4 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
TWI897902B (zh) 人類染色體9開讀框72 (C9ORF72) iRNA劑組成物及其使用方法
JP2026028255A (ja) ハンチンチン（ＨＴＴ）ｉＲＮＡ剤組成物およびその使用方法
JP2024536811A (ja) 微小管関連タンパク質タウ（ＭＡＰＴ）ｉＲＮＡ製剤組成物およびその使用方法
WO2021222065A1 (en) Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
WO2022026531A1 (en) Atxn2 irna compositions and methods of use thereof for treating or preventing atxn2-associated neurodegenerative diseases
JP2024512635A (ja) ハンチンチン（ＨＴＴ）ｉＲＮＡ剤組成物およびその使用方法
JP2024528503A (ja) ロイシンリッチリピートキナーゼ２（ＬＲＲＫ２）ｉＲＮＡ剤組成物およびその使用方法
EP4225917A1 (en) G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
JP2023511434A (ja) ロイシンリッチリピートキナーゼ２（ＬＲＲＫ２）ｉＲＮＡ剤組成物およびその使用方法
JP2024522068A (ja) ナトリウム－グルコース共輸送体２（ｓｇｌｔ２）ｉｒｎａ組成物およびその使用方法
JP2024509783A (ja) プリオンタンパク質（ｐｒｎｐ）ｉｒｎａ組成物およびその使用方法
JP2024508714A (ja) スーパーオキシドジスムターゼ１－（ＳＯＤ１－）関連神経変性疾患を治療または予防するためのスーパーオキシドジスムターゼ１（ＳＯＤ１）ｉＲＮＡ組成物およびその使用方法
EP4232582A1 (en) Mucin 5b (muc5b) irna compositions and methods of use thereof
US12534731B2 (en) Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof
EP4518871A1 (en) Actin-binding lim protein 3 (ablim3) irna agent compositions and methods of use thereof
JP2024521907A (ja) ヒト９番染色体オープンリーディングフレーム７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ剤組成物及びその使用方法
EP4423272A2 (en) Huntingtin (htt) irna agent compositions and methods of use thereof
JP2024528417A (ja) フィラミンａ（ｆｌｎａ）をサイレンシングするためのｉｒｎａ組成物および方法
WO2022192519A1 (en) Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
WO2023141314A2 (en) Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
US20240200077A1 (en) Stearoyl-coa desaturase 5 (scd5) irna agent compositions and methods of use thereof

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428